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Purpose: Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. 
Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) 
represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and 
retrospectively reviewed the efficacy and safety of this approach. 
Methods: Patients diagnosed with intraocular RB between January 2000 and December 2011 at 
Severance Children’s Hospital, Yonsei University, were reviewed. Before February 2010, the primary 
treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for 
RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy were used as “last 
resort” treatments just prior to enucleation at the time of progression or recurrence during primary 
treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. 
Results: We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 
eyes, of which, 60.0% were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3% 
at early RE stages and 81.8% at advanced RE stages (P=0.028). At 36 months, EFS was significantly 
higher in the IAC/CTX group than in the non-IAC/CTX group (100% vs. 40.0%, P=0.016). All 5 patients 
treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV–V). 
Conclusion: Despite the limitation of a small sample size, our work shows that an alternative combined 
approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.
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Introduction
Retinoblastoma (RB) is known as one of the common primary malignant intraocular 
tumor of childhood which occurs in 1% of all tumors in infancy, 12 out of 2 million 
children under 4 years old and the median age is under 12 months old. There are two 
main forms of RB; genetic and somatic. Patients with the germline mutation of Rb1 gene 
(genetic form) have significant risk of secondary malignancy increased with radiation 
treatment for the primary cancer
1). 
External beam radiotherapy (EBRT) or enucleation was considered to be the only 
definite treatment in the past. The modalities achieve high survival rate, but also have 
significant limitations. Enucleation is performed in high stage unilateral RB (vitreous 
seeding), more progressed eye in bilateral eyes, vitreous hemorrhage, and complicated 
cataract. It is also performed as the final treatment of RB in the failure of other treatment 
modalities. EBRT can cause serious complications such as cataract, facial growth disturbance, 
optic neuropathy, and secondary malignancy. To improve survival, prevent serious com­
plications and preserve eye sight, many other treatment modalities than enucleation 255 http://dx.doi.org/10.3345/kjp.2013.56.6.254
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and EBRT have been tried. Systemic control is necessary with 
chemotherapy especially in high risk RB
2). The role is to increase 
long­term survival, reduce complications from EBRT, and avoid 
enucleation. Focal therapies such as laser photocoagulation, 
thermotherapy, and cryotherapy were effective in small tumors 
posterior to the equator of the eye
1,3). The application of systemic 
chemotherapy and focal therapy greatly increased the survival 
rate and reduce complications.
Intra­arterial chemotherapy (IAC) with melphalan or other 
chemotherapeutic agents was lately introduced in the treatment 
of RB. IAC had been tried as the second line treatment after the 
failure of chemotherapy and focal treatment. Recently, IAC has 
been started to be used as first line treatment. IAC was effective 
for Reese Ellsworth (RE) stage IV to V, in which chemotherapy 
had not been effective. IAC had more than 70% of ocular salvage 
rates as a primary treatment. Success rates are inferior when it 
is used as the second line treatment, that is, after the failure of 
systemic chemotherapy or radiotherapy
4,5). 
In this study, the primary treatment of RB was combined 
chemotherapy with supplemental focal therapy, or IAC. When 
only IAC is applied as a sole primary treatment, it has some risks of 
recurrence or metastasis because pathologic risk factors can  not 
be assessed. In order to determine the need for adjuvant chemo­
therapy after enucleation, pathologic examination of enu  cleated 
specimen is necessary for exact risk assessment and need of 
adjuvant chemotherapy. High risk features include anterior 
chamber seeding, and choroidal involvement for metastasis. We 
added systemic adjuvant chemotherapy to IAC to prevent me­
tastasis and recurrence
6). We hereby analyzed retrospectively the 
efficacy and safety of the combined alternate IAC and chemo­
therapy approach. 
Materials and methods
1. Patients
Total of 35 patients with intraocular RB who were evaluated 
and treated between January 2000 and December 2011 at Severance 
Children’s Hospital, Yonsei University Health System were 
identified in this study. Among 35 patients, 16 were excluded 
due to insufficient information and follow up loss. Data was 
collected retrospectively for the remaining 19 patients with total 
of 25 eyes and numbered each eyes. There were 6 bilateral RB 
patients and each eye was numbered from 11 through 22. Age 
at diagnosis, gender, initial symptom at diagnosis, laterality, RE 
stage, and type of treatments, were assessed. 
2. Stage 
RE stage is the classification of intraocular RB to show progno­
stic significance for maintenance of sight when enucleation and 
EBRT were primary treatment options
7­12). Ophthalmologists exa­
mined the tumor status, RE stage, and assessed the need for focal 
therapy. 
3. Treatment 
We divided the patients to 2 main groups, IAC/CTX group and 
non­IAC/CTX group. Non­IAC/CTX group include following sub­
categories; chemotherapy (CTX group), chemotherapy followed 
by high­dose chemotherapy (HDCTX group), and chemotherapy 
followed by EBRT and HDCTX (EBRT/HDCTX group). All RB 
patients without metastasis received chemotherapy or IAC as the 
primary treatment in order to avoid enculeation. Before 2010, the 
primary treatment for all RB was CTX. Since 2010, primary treat­
ment for all RB has been IAC. EBRT or HDCTX was the last resort, 
just prior to enucleation at the time of progression or recurrence 
during primary treatments. In bilateral RB, we performed primary 
treatment without enucleation of more ag  gressive eye at the 
diagnosis. 
1) Systemic chemotherapy and focal therapy
Systemic chemotherapy was performed to all patients and to 
all stages of RB. Patients received chemotherapy with or without 
focal therapies such as laser photocoagulation, transpupillary 
thermotherapy, and cryotherapy. Decision of need for focal 
therapy was determined by ophthalmologists through detailed 
examination under general anesthesia. Chemotherapy regimen 
consisted of carboplatin (D1 and D2, 200 mg/m
2 or 6.7 mg/kg), 
vincristine (D1, 1.5 mg/m
2 or 0.05 mg/kg), etoposide (D1 and D2, 
150 mg/m
2 or 5 mg/kg), and cyclosporin (D1 and D2, 360 mg/m
2 
or 12 mg/kg) in 3 weeks. Weight based dosage calculation were 
applied to the patients with weight less than 10 kg or age less 
than 36 months old. 
2) EBRT and HDCTX
EBRT was mainly performed in patients diagnosed before 
year 2008. EBRT or HDCTX with peripheral blood stem cell 
transplantation was applied at the time of progression or 
recurrence after the primary treatment in order to preserve eye 
globes. 
3) IAC 
Since year 2010, IAC was applied as first line therapy performing 
alternately with chemotherapy to all patients who were diagnosed 
as RB without metastasis (IAC/CTX approach). Interval between 
IAC and chemotherapy was 3 weeks and we performed maximal 
6 cycles of IAC or chemotherapy for each. IAC was performed by 
skilled radiologist specialized in intervention procedure. Femoral 
arterial puncture and insertion of Hunter catheter passing through 
aorta, common carotid artery, internal carotid artery, and finally 
Marathon microcatheter positioned at the ostium of ophthalmic 
artery. Melphalan (3–7.5 mg/kg/injection) was infused directly into 
ophthalmic artery for 30 minutes. http://dx.doi.org/10.3345/kjp.2013.56.6.254
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4) Enucleation
Enucleation was performed as the final treatment in high stage 
RB at the time of progression during the primary treatment or 
recurrence with no expected chance of preservation of eye sight. 
5) Adverse effects
Adverse events were assessed by Common Terminology Criteria 
for Adverse Events (CTCAE) ver. 4.0.  
4. Statistical analysis
Enucleation rate (ER) was defined as the proportion of enu­
cleation according to the treatment groups and RE stage. 
Enucleation­free survival (EFS) was defined as the duration 
(months) from diagnosis to the enucleation. EFS was assessed 
at 60 months of follow­up for RE stage and 36 months for the 
treatment modalities because of the shorter median follow­up 
duration of the IAC/CTX group. Progression­free survival (PFS) 
was from the diagnosis to the event of receiving EBRT, HDCTX, 
and enucleation, whichever comes first. Statistical analysis was 
performed by using PASW ver. 18.0 (IBM Co., Armonk, NY, 
USA). Chi­square analysis was used for comparison of discon­
tinuous variables, Mann­Whitney U test for nonparametic signi­
ficance test, and Kaplan­Meier survival analysis for EFS and PFS. P 
value of <0.05 was considered statistically significant. 
Results
1. Demographic characteristics
Median age at the time of diagnosis was 11.9 months old 
(range, 1.4 to 75.6 months). Six patients were diagnosed with bi­
lateral RB (31.6%) and 13 were unilateral. Total eye number was 
25. Leukocoria was the most common feature presented at the 
time of diagnosis (14/25, 56.0%), strabismus (5/25, 20.0%) was 
the second. According to RE stage, 60.0% of total eyes (15/25) 
were in advanced stage (IV and V). All patients survived with 
median follow up duration of 47.3 months (range, 12.2 to 134.4 
months) (Table 1).
2. Treatment results
Distribution of patients according to the type of treatment mo­
dalities are as the following; IAC/CTX group was 5 eyes (20.0%), 
in non­IAC/CTX group was 20 eyes (80.0%). In non­IAC/CTX 
group, CTX group was 15 eyes (60.0%) with median of 10 cycles 
(3 to 20), HDCTX group was 2 eyes (8.0%), and EBRT/HDCTX 
group was 3 eyes (12.0%), respectively. ER according to the RE 
stage of RB was 30.0% (3/10) in early stage (I to III) with median 
eye survival time of 14.1 months (range, 1.0 to 94.3 months) 
and 60.0% (9/15) in advanced stage (IV to V) with median 31.3 
months (range, 0.6 to 24.6 months) (Table 2). In all 25 eyes, ER 
was 48.0% (12/25). No eyes were enucleated in IAC/CTX group 
(0/5) whereas 60.0% (12/20) of eyes in non­IAC/CTX group were 
enucleated (P=0.016). Among enucleated eyes in non­IAC/CTX 
group, 53.3% (8/15) was CTX group and 100.0% (2/2) in HDCTX 
group, and 66.7% (2/3) in EBRT/HDCTX group (P=0.033) (Table 3). 
In non­IAC/CTX group, ER according to the RE stage of RB was 
33.3% (3/9) in early stage (I to III) and 81.8% (9/11) in advanced 
Table 1. Baseline demographics of the study participants 
Variable Value
Sex 
  Male  10 (52.6)
  Female 9 (47.4)
  Total (patients) 19 (100)
Age at diagnosis (mo) 11.9 (1.4–75.6)
Laterality
  Unilateral 13 (68.4)
  Bilateral 12 (31.6)
  Total (eyes) 25 (100)
Symptom at diagnosis
  Leukocoria 14 (56.0)
  Strabismus 5 (20.0)
  Periorbital swelling 2 (8.0)
  Conjunctival injection 2 (8.0)
  Visual disturbance 2 (8.0)
Rb1 gene mutation
  Mutation 2 (10.5)
  No deletion 11 (57.9)
  Not done 6 (31.6)
RE stage*
  I 3 (12.0)
  II 2 (8.0)
  III 5 (20.0)
  IV 1 (4.0)
  V 14 (56.0)
  Total (eyes) 25 (100)
Types of treatment*
  IAC/CTX 5 (20.0)
  Non-IAC/CTX 
    CTX 15 (60.0)
    HDCTX 2 (8.0)
    EBRT/HDCTX 3 (12.0)
  Total (eyes) 25 (100)
Values are presented as number (%) or median (range).
IAC/CTX, alternative combined approach or intra-arterial and chemotherapy; 
CTX, systemic chemotherapy with or without focal therapy; HDCTX, high-
dose chemotherapy as stemcell transplantation; EBRT, external beam radiation 
therapy; Focal, laser photocoagulation or transpupillary thermotherapy or 
cryotherapy.
*Reese Ellsworth (RE) stage and treatment were categorized with the total 
number of eyes (25 eyes). 257 http://dx.doi.org/10.3345/kjp.2013.56.6.254
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stage (IV to V) (P=0.028). HDCTX and EBRT/HDCTX were all 
performed in patients with advanced RE stage (IV to V).  
3. Eye preservation rate of IAC/CTX and its adverse events
Four patients with total of 5 eyes received IAC (Table 4). Four 
out of 5 were in stage V and one was stage II. Melphalan dosage 
was 3 to 7.5 mg and IAC was delivered with median of 1 cycle 
(range, 1 to 5) and CTX was delivered with median of 6 cycles 
(range, 3 to 9 cycles) in IAC/CTX group. All eyes were preserved 
with median of 24.2 months of follow­up (range, 12.2 to 36.5 
months). ER in IAC/CTX group was significantly lower than non­ 
IAC/CTX groups (0% [0/5] vs. 60.0% [12/20], P=0.016). 
Grade 1 periorbital swelling was presented eye Aa in 2 weeks 
after IAC but it had resolved spontaneously. Grade 2 retinal detach­
ment was shown in 60.0% (3/5). There was no grade 3 or higher 
neutropenia or other adverse events (Table 5). 
4. EFS and PFS
We evaluated EFS according to the stage and treatment moda­
lities. Mean EFS according to RE stage at 60 months was 66± 
13.5% in early stage (I to III) and 33.0±12.1% in advanced stage 
(IV to V) (P=0.237) (Fig. 1). Among patients in non­IAC/CTX 
group, the mean EFS was 67.5±12.9% in early stage (I to III) and 
33.1±9.2% in advanced stage (IV to V) (P=0.028). EFS at 36 months 
of IAC/CTX group was significantly higher than in non­IAC/
CTX group (100.0% vs. 40.0±31.2%, P=0.016) (Fig. 2). PFS at 36 
months was 100% in IAC/CTX and 35.0±9.8% in non­IAC/CTX 
(P=0.012) (Fig. 3). 
Table 2. Enucleation according to Reese Ellsworth (RE) stage
RE stage Enucleation (%)
Early 3/10 (30.0)
  I 0/3 (0)
  II 0/2 (0)
  III 3/5 (60.0)
Advanced 9/15 (60.0)
  IV 1/1 (100)
  V 8/14 (57.1)
Total (eyes) 12/25 (48.0)
P value  0.028
P value on effect of RE stage on enucleation versus eye preservation analyzed 
by Pearson chi square.
Table 3. Distribution of number of eyes, enucleation according to Reese 
Ellsworth (RE) stage, and type of treatment
Treatment
RE stage Enucleation/total 
no. of eyes (%) I II III IV V
IAC/CTX 0/0 0/1 0/0 0/0 0/4 0/5 (0)
Non-IAC/CTX 0/3 0/1 3/5 1/1 8/10 12/20 (60.0)
CTX 0/3 0/1 3/5 0/0 5/6 8/15 (53.3)
HDCTX 0/0 0/0 0/0 0/0 2/2 2/2 (100)
EBRT/HDCTX 0/0 0/0 0/0 1/1 1/2 2/3 (66.7)
Total (no. of eyes) 0/3 0/2 3/5 1/1 8/14 12/25 (48.0)
IAC/CTX, alternative combined approach or intra-arterial and chemotherapy; 
CTX, systemic chemotherapy with or without focal therapy; HDCTX, high-
dose chemotherapy as stemcell transplantation; EBRT, external beam radiation 
therapy; Focal, laser photocoagulation or transpupillary thermotherapy or 
cryotherapy.
Table 4. Summary of patients undergoing intra-arterial chemotherapy 
treatment
Patient (eye no.) Aa (21) Ab (22) B (23) C (24) D (25)
Age at diagnosis (mo) 4.2 4.2 13.8 29.5 36.3
Laterality Bilateral Bilateral Unilateral Unilateral Unilateral
RE stage V V V V II
Melphalan dose (mg) 7.5 7.5 7.5 3 3
No. of IAC cycles 1 1 2 6 4
Cycles of CTX before IAC 3 3 9 7 6
Enucleation No No No No No
Eye preservation period 
  (mo)
29.8 29.8 36.5 18.5 12.2
RE, Reese Ellsworth; IAC, intra-arterial chemotherapy; CTX, systemic 
chemotherapy with or without focal therapy. 
Table 5. Distribution of adverse events according to the Common Termi-
nology Criteria for Adverse Events (CTCAE*) in relation to therapeutic 
procedure or chemotherapy
Adverse event 
Treatment
CTX (n=15) IAC/CTX (n=5)
Cycle 10 (3–20) 6 (3–9)
Anemia grade 3
† 2/15 (13.3) -
Febrile neutropenia
‡ grade 3 3/15 (20.0) -
Conjunctivitis grade 2 1/15 (6.7) -
Retinal detachment grade 3 2/15 (13.3) -
Constipation grade 3 2/15 (13.3) -
Vomiting grade 2 3/15 (20.0) -
Diarrhea grade 3 1/15 (6.7) -
Ileus grade 3 2/15 (13.3) -
Hyponatremia grade 3 2/15 (13.3) -
Seizure grade 3 2/15 (13.3) -
Urinary tract infection grade 3 1/15 (6.7) -
Retinal detachment grade 2 - 3/5 (60.0)
Periorbital swelling grade 1 - 1/5 (20.0)
Values are presented as median (range) or number (%).
CTX, systemic chemotherapy with or without focal therapy; IAC/CTX, alternative 
combined approach or intra-arterial and chemotherapy.
*Comparison of adverse events according to CTCAE ver. 4.0. 
†Anemia grade 3: 
(hemoglobin <8.0 g/dL). 
‡Febrile neutropenia: (absolute neutrophil count <1,000/ 
mm
3 and single temperature of >38.3℃).http://dx.doi.org/10.3345/kjp.2013.56.6.254
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Discussion
In order to preserve eyes and eye sight, treatment other than 
enucleation and EBRT have been tried. Systemic chemotherapy 
is preferred to the enucleation and EBRT, because those approaches 
cause eye globe loss and other significant ocular and systemic 
complications
3). Unilateral RB is usually massive and has higher 
need for enucleation. It is possible to preserve eye sight when the 
size is small. In a study with 30 patients, 11% of RE stage II or 
III, 60% of stage IV, and 100% of stage V required enucleation 
or EBRT
13). Several recent studies have shown that multi agent 
systemic chemotherapy with conjugation of focal treatment 
achieved 90% of radiation and EFS for early stage RB (RE stage I 
to III) and 30% for more advanced RB (RE stage IV to V)
1). In this 
study, mean EFS according to RE stage at 60 months was 66.0% 
in early stage (I to III) and 33.0% in advanced stage (IV to V). In 
non­IAC/CTX group (traditional treatment group), the efficacy 
of the CTX in advanced RE stage was extremely unfavorable; 
81.1% (9/11) was enucleated. EFS at 36 months in IAC/CTX 
group was 100% and all eyes were preserved even if 80% of eyes 
(4/5) were in advanced stage (RE stage V). It means that alternate 
IAC and chemotherapy approach improved EFS than other 
modalities. 
In the past 5 years, IAC became promising approach for eye 
preservation and avoidance of chemotherapy complications. It 
has significantly reduced the enucleation even in the advanced 
intraocular RB (RE stage Va and Vb) and with minimized toxicity 
of systemic chemotherapy
2). At first, IAC was tried as the second 
line treatment. A second line IAC study of 15 eyes of RB with 
retinal detachment showed, tumor regression in 27.0% (4/15). 
Eye globe was preserved in 71.0% (5/7) with total retinal detach­
ment and 75% (6/8) with partial retinal detachment
14). IAC has 
become the primary treatment of advanced stage in RB
4,5). A large 
study of IAC for eyes with stage V showed EFS at 2 years was 
80.0% as the primary treatment, and 51.5% as the second line 
treatment
15).
IAC/CTX approach was recently adopted in this institution 
as the primary treatment for RB. Many studies showed efficacy 
of adjuvant CTX after enucleation for the patients with high 
risk factors such as involvement of anterior segment, surgical 
margin of optic nerve, postlaminar optic nerve, and choroid 
plexus
6,13,16,17). Because there is a difficulty to determine exact 
metastatic risk before the enucleation and pathologic evaluation, 
we performed IAC/CTX for advanced RE stage patients. This 
combined approach is the unique; most of articles on the IAC 
approach gave IAC only as the first line or second line treatment 
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Fig. 1. Enucleation-free survival according to Reese Ellsworth (RE) stage. RE 
stages I–III are described as “early stage” and stages IV–V are described 
as “advanced stage”.
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Fig. 2.  Enucleation-free survival according to type of treatment. IAC/CTX, 
alternative combined approach or intra-arterial chemotherapy.
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Fig. 3. Progression-free survival according to retinoblastoma treatment. 
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for RB. 
Generally, IAC do not have significant adverse events. Most 
of the studies report no systemic toxic effects of infused chemo­
therapeutic agents via arter. Local complication might occur in 
infused eyes
14). Bianciotto et al.
18) also reported vascular abnor­
malities observed through fluorescence angiography such as 
ophthalmic artery occlusion, spasm, and branch retinal artery 
stenosis. Despite of local complications, retinal functions are well 
preserved
1,2,15,18­20).
Only few adverse events were observed in IAC/CTX group in 
our study. There were no grade 3 or 4 adverse events. In compa­
rison to patients receiving only CTX, the number of cycles of 
chemotherapy in IAC/CTX group was less than in non­IAC/CTX 
group (median of 6 cycles [range, 3 to 9 cycles] vs.10 cycles [range, 
3 to 20 cycles], P=0.083). The fewer cycles of CTX in IAC/CTX 
group may explain minimal adverse event in the group comparing 
with non­IAC/CTX group
15,19).
This study but has some limitations. The number of IAC/CTX 
group was small and follow­up duration was relatively shorter 
than other groups. In order to confirm the long term efficacy of 
combined approach for metastasis prevention, we need at least 5 to 
10 years of follow­up taking the median survival of RB patients 
into consideration. ER was lower and EFS was higher in IAC/CTX 
group for advanced stage but the interaction between stage and 
ER/EFS could not be assessed because the number of patients in 
IAC/CTX group was limited. 
In summary, IAC/CTX approach was the effective treatment 
for preservation of eye globes. The IAC/CTX approach is another 
choice for the treatment of RB and the approach could be delivered 
safely without significant adverse events.
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